Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Candel Therapeutics (CADL) Income from Continuing Operations (2020 - 2023)

Candel Therapeutics' Income from Continuing Operations history spans 4 years, with the latest figure at 10576000.0 for Q4 2023.

  • For Q4 2023, Income from Continuing Operations fell 37.35% year-over-year to 10576000.0; the TTM value through Dec 2023 reached 38905000.0, down 12.44%, while the annual FY2024 figure was 30195000.0, 22.39% up from the prior year.
  • Income from Continuing Operations for Q4 2023 was 10576000.0 at Candel Therapeutics, down from 9028000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2619000.0 in Q2 2020 and bottomed at 10576000.0 in Q4 2023.
  • The 4-year median for Income from Continuing Operations is 8363000.0 (2021), against an average of 7712928.57.
  • The largest annual shift saw Income from Continuing Operations plummeted 103.02% in 2021 before it increased 0.65% in 2022.
  • A 4-year view of Income from Continuing Operations shows it stood at 6077000.0 in 2020, then fell by 27.53% to 7750000.0 in 2021, then grew by 0.65% to 7700000.0 in 2022, then plummeted by 37.35% to 10576000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Income from Continuing Operations are 10576000.0 (Q4 2023), 9028000.0 (Q3 2023), and 9770000.0 (Q2 2023).